Drug Discovery

BioMarin acquires Amicus Therapeutics for $4.8bn

BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal for a total equity value of nearly $4.8bn.

Sun Pharma to acquire Organon for $11.75bn

Sun Pharmaceutical Industries has signed a definitive agreement to acquire Organon in a transaction with an enterprise valuation of $11.75bn in cash, paying $14.00 per share for all outstanding shares.

OZMOSI and Planview partner to enhance pharmaceutical data integration

OZMOSI and Planview have formed a partnership to support pharmaceutical organisations by integrating Ozmosi’s structured, machine-readable clinical datasets with Planview’s AI-driven portfolio planning platform.

Cumberland to sell drug portfolio to Apotex for $100m

Cumberland Pharmaceuticals has agreed to sell its branded commercial drug portfolio to Canadian pharmaceutical company Apotex for $100m in cash.

Sanofi receives FDA approval for Tzield in paediatric diabetes

Sanofi has received approval from the US Food and Drug Administration (FDA) for a supplemental biologic licence application for Tzield (teplizumab-mzwv), allowing its use to delay stage 3 type 1 diabetes (T1D) onset in children as young as one year diagnosed with stage 2 T1D.

MSD teams up with Google Cloud on agentic AI transformation

Merck & Co (MSD) and Google Cloud have formed a multi-year partnership, investing up to $1bn, to advance agentic AI enterprise transformation.

BioAegis and Prenosis partner for inflammatory disease therapies

BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases.

Health Canada approves Biocon’s two denosumab biosimilars

Biocon has received a Notice of Compliance from Health Canada for Bosaya (denosumab) and Vevzuo (denosumab), both biosimilars referencing Prolia and Xgeva, respectively.

Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy

Pfizer and Astellas have received the US Food and Drug Administration (FDA) acceptance for priority review of their supplemental biologics licence application (sBLA) for perioperative Padcev (enfortumab vedotin-ejfv) combined with the PD-1 inhibitor Keytruda (pembrolizumab) for muscle-invasive bladder cancer (MIBC).